Iproniazid in Depressive Syndrome

West, Eric D.; Dally, Peter

doi:10.1136/bmj.2.5149.433

Cited by 9 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atypical depressives considered preferentially responsive to MAOIs have often been noted to also have prominent anxiety features. West & Dally (18) and Sargant (19) noted hysterical features, phobias, initial insomnia and prominent anxiety in the profile of iproniazid responders. Robinson et al (14) showed that phenelzine was superior to amitriptyline in outpatient nonmelancholic major depressives with panic features, but not in the subsample without panic features.…”

Section: Mixed Anxiety and Depressionmentioning

confidence: 99%

“…West & Dally (18) found both phenelzine 45 mg/day and imipramine 150 mg/day superior to placebo in a double-blind trial in patients with panic attacks, which they called endogenous anxiety. Phenelzine was slightly superior to imipramine in reducing social disability and symptom severity as well as phobic avoidance measured after 12 weeks.…”

Section: Panic Disorder and Agoraphobiamentioning

confidence: 99%

See 1 more Smart Citation

Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders

Liebowitz

Hollander

Schneier

et al. 1990

Acta Psychiatr Scand

View full text Add to dashboard Cite

In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive‐compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO‐A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.

show abstract

Section: Mixed Anxiety and Depressionmentioning

confidence: 99%

Section: Panic Disorder and Agoraphobiamentioning

confidence: 99%

Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders

Liebowitz

Hollander

Schneier

et al. 1990

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…Open trials with iproniazid (West & Dally, 1959;Sargant, 1961) suggested that the MAOIs were efficacious for phobic anxiety, while Kelly et al (1970) first reported the efficacy of MAOIs (phenelzine) in patients with panic disorder. Sheehan et al (1980) found both phenelzine, 45 mg/day and imipramine, 150 mg/day to be superior to placebo in patients with 'endogenous anxiety' who suffered panic attacks.…”

Section: Monoamine Oxidase Inhibitorsmentioning

confidence: 99%

Antidepressants in Panic Disorders

Liebowitz

1989

Br J Psychiatry

View full text Add to dashboard Cite

The efficacy of antidepressants for panic disorders has had major effects on our understanding of the classification, pathophysiology, and treatment of anxiety disorders. Psychiatric practice has also been significantly affected, but important issues remain unresolved, such as the mechanisms of therapeutic effect, optimal duration of therapy to minimise relapse, and the interaction and sequencing of medication with cognitive behavioural treatments.

show abstract

“…When we began our research, the literature described a heterogeneous patient population that appeared to benefit from MAOls (West & Dally, 1959;Dally & Rhode, 1961;Sargent, 1961;Polit & Young, 1971;Quitkin et al, 1979;Davidson et al, 1982). There appeared to be at least two patient types: the V type, with vegetative symptoms such as hypersomnia, hyperphagia, lethargy, and reversed diurnal variation; and the A type, in which depressive symptoms and anxiety, panic, and phobia were present (Davidson et ai, 1982).…”

mentioning

confidence: 99%

“…There appeared to be at least two patient types: the V type, with vegetative symptoms such as hypersomnia, hyperphagia, lethargy, and reversed diurnal variation; and the A type, in which depressive symptoms and anxiety, panic, and phobia were present (Davidson et ai, 1982). However, it was not always clear that depressive symptoms were present, since one group of researchers stated, "Often the original depressive symptoms have become masked by phobic anxiety" (West & Dally, 1959).…”

mentioning

confidence: 99%

Columbia Atypical Depression

et al. 1993

View full text Add to dashboard Cite

We summarise a series of studies using a MAOI to help establish the validity of a subgroup of depressives referred to as atypical depressives. Patients with reactive mood meeting DSM-III criteria for depressive illness who had associated atypical features (which include hyperphagia, hypersomnolence, leaden paralysis, and rejection sensitivity) were randomised to imipramine, phenelzine and placebo. Non-responders were crossed over, and in all there were over 400 patient trials. Phenelzine consistently was found to be superior to imipramine. Only in trials which included patients lacking atypical, vegetative symptoms was imipramine found to equal phenelzine. We conclude that the researcher and the clinician should consider the relevance of the atypical depressive syndrome.

show abstract

Iproniazid in Depressive Syndrome

Cited by 9 publications

References 0 publications

Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders

Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders

Antidepressants in Panic Disorders

Columbia Atypical Depression

Contact Info

Product

Resources

About